Skip to main content

Table 1 Baseline demographics and clinical characteristics

From: Changes in CT morphology can be an independent response marker for patients receiving regorafenib for colorectal liver metastases: retrospective pilot study

  Number of patients %
Age, years
 Median 63
 Range 39–83
Sex
 Male 8 80
 Female 2 20
Primary tumor
 Colon 2 20
 Rectum 8 80
Extrahepatic disease
 Present 10 100
 Absent 0 0
Number of prior chemotherapy lines
 1 1 10
 2 3 30
 3 3 30
 4 3 30
Prior chemotherapy regimen
 Oxaliplatin 9 90
 Irinotecan 8 80
 Bevacizumab 10 100
 Cetuximab 1 10
 Panitumumab 4 40
 TAS-102 3 30
RAS status
 Wild 5 50
 Mutation 5 50